Analysts Set Expectations for Vanda Pharmaceuticals Inc.’s FY2017 Earnings (VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Jefferies Group lowered their FY2017 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research report issued on Monday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings of ($0.53) per share for the year, down from their previous forecast of ($0.52). Jefferies Group has a “Buy” rating and a $21.00 price objective on the stock. Jefferies Group also issued estimates for Vanda Pharmaceuticals’ Q4 2017 earnings at ($0.19) EPS, FY2018 earnings at ($0.34) EPS, FY2019 earnings at $1.37 EPS, FY2020 earnings at $1.30 EPS and FY2021 earnings at $1.71 EPS.
VNDA has been the topic of a number of other research reports. Zacks Investment Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 5th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. HC Wainwright set a $18.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average target price of $21.29.
Vanda Pharmaceuticals (NASDAQ:VNDA) opened at 16.80 on Wednesday. Vanda Pharmaceuticals has a 12 month low of $12.70 and a 12 month high of $18.99. The firm’s 50-day moving average is $17.45 and its 200-day moving average is $15.62. The firm’s market capitalization is $753.61 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.18. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. Vanda Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.01 earnings per share.
A number of institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc boosted its position in Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the period. Virginia Retirement Systems ET AL bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $193,000. Dynamic Technology Lab Private Ltd bought a new stake in Vanda Pharmaceuticals during the first quarter worth approximately $196,000. Kopp Investment Advisors LLC bought a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $196,000. Finally, American International Group Inc. boosted its position in Vanda Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.